Work

Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies

Year: 2026
Type: article
Abstract: Venetoclax combined with azacitidine has transformed the treatment of newly diagnosed acute myeloid leukemia in patients ineligible for intensive chemotherapy. However, prolonged cytopenias, infectious complications, and treatment interruptions have prompted increasing use of abbreviated venetoclax schedules. This narrative review critically examines the evidence supporting modifications in treatment duration and daily dose, with emphasis on the balance between antileukemic efficacy and tolerability. Retrospective studies, including the analysis by Willekens and colleagues, suggest that shorter schedules may reduce selected measures of hematologic toxicity and supportive-care burden while maintaining encouraging remission rates. Nevertheless, these findings are vulnerable to selection bias and cannot establish equivalence. Importantly, the randomized OPTI-AML trial did not demonstrate noninferiority of a 14-day induction schedule compared with 28 days and identified a potentially relevant reduction in early complete remission among patients harboring NPM1 and/or IDH2 mutations. These observations suggest that the consequences of shortening venetoclax exposure may depend on treatment phase and leukemia biology. We discuss pharmacokinetic interactions, post-remission cytopenia management, and molecularly informed treatment adaptation, and highlight the need for prospective studies that jointly evaluate efficacy, toxicity, and patient-centered outcomes.
Source: Cancers
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7226002494
FWCI:
Cites: 34
Cited by:
Related to: 10